Divi's Laboratories Shares Rally 6% In Early Trade After Q2FY27 Profit Jumps 64% To ₹1,127 Crore; EBITDA Margin Expands To 42.6%

  • Posted: 09 Nov 2026, 10:55 AM IST
  • 1.5 Min. Read
Add Preferred News SourceAdd Preferred News Source
Divi's Laboratories Shares Rally 6% In Early Trade After Q2FY27 Profit Jumps 64% To ₹1,127 Crore; EBITDA Margin Expands To 42.6%
Divi's Laboratories shares rallied after the company posted healthy growth in its September quarter earnings.
Summary

Shares of Divi's Laboratories gained following better-than-expected September quarter earnings, supported by higher profitability, improved operating margins and strong performance across its key business segments.

Shares of Divi’s Laboratories rose 6% in early trading on Monday, 9 November, after the pharmaceutical company reported a strong set of September quarter (Q2FY27) results, with revenue, net profit and operating margins beating analyst estimates.

The company's consolidated net profit increased 64% year-on-year (YoY) to ₹1,127 crore in Q2FY27, compared with ₹689 crore in the corresponding quarter last year.

At 10:25 am, Divi’s Laboratories shares were up 5.52% on the National Stock Exchange (NSE).

Shares Extend Rally After Q2 Results

The stock had already gained over 8% during the Muhurat Trading session on Sunday, 8 November. The special Diwali trading session saw buying interest in the pharmaceutical company's shares after its strong quarterly earnings lifted investor sentiment.

Monday's gains extended the recent rally in the stock. Divi's Laboratories shares have risen over 14% in the past week and more than 17% over the past month.

The stock has risen over 76% since the start of 2026. Its gains over the one-year, three-year and five-year periods stand at more than 62%, nearly 220% and around 115%, respectively.

Divi's Laboratories Q2 FY27 Results

As per the Q2 FY2026-27 results, the company’s operating performance has remained strong. Earnings before interest, tax, depreciation and amortisation (EBITDA) surged 76% YoY to ₹1,566 crore, against ₹888 crore in Q2FY26. EBITDA margin expanded to 42.6% from 32.7% in the year-ago quarter.

Consolidated revenue from operations stood at ₹3,676 crore in Q2FY27. It was ₹2,715 crore in the corresponding quarter of the previous financial year, marking a 35.4% increase.

The generics and custom synthesis segments performed well during the quarter. Favourable currency movements and business opportunities in the GLP-1 space also added to the company's growth.

Also Read - Bonus Issues, Stock Splits and Dividends: Dabur India, HUL, ONGC Among 76 Stocks With Record Dates From 9–13 November

This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer

About the Author
Vishwa Ved
Vishwa Ved

Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.

At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.

When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.

Latest News